The article is devoted to the scientific justification of organizational and economic approaches to improving medical and pharmaceutical care for patients with psoriasis on the basis of setting the optimal medicinal budget of a specialized healthcare organization. The research was based on the systematization of federal clinical recommendations data and the medical records of in-patients with a diagnosis of psoriasis treated at the twenty-four-hour in-patient hospital of the Kursk Regional Clinical Dermatovenerologic Dispensary. Collected data was used for the analysis of the medicines assortment for the actual therapy of psoriasis and for the identification of the structure of the prescribed assortment depending on the intensity of consumption among the groups under ATS-classification. As a result of the integrated ABC/XYZ analysis of drug consumption, priority medicines for procurement were identified and classified in four conditional status groups. Moreover, the cost estimation of the medicinal budget was made in context of general framework and for each status group separately.